Physician perceptions and use of reduced‐dose direct oral anticoagulants for extended phase venous thromboembolism treatment

BACKGROUND: The direct oral anticoagulants (DOACs), apixaban and rivaroxaban, have been studied for extended‐phase treatment of venous thromboembolism (VTE). Yet, scant evidence exists surrounding clinician practice and decision‐making regarding dose reduction. AIMS: Report clinician practice and ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Groat, Danielle, Martin, Karlyn A., Rosovsky, Rachel P., Sanfilippo, Kristen M., Gaddh, Manila, Kreuziger, Lisa Baumann, Eyster, M. Elaine, Woller, Scott C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175245/
https://www.ncbi.nlm.nih.gov/pubmed/35702588
http://dx.doi.org/10.1002/rth2.12740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175245/
https://www.ncbi.nlm.nih.gov/pubmed/35702588
http://dx.doi.org/10.1002/rth2.12740

Ejemplares similares